About RxTariff

Why We Built This

When the Trump administration signed the Section 232 pharmaceutical tariff proclamation on April 2, 2026, millions of Americans had no easy way to find out whether their prescriptions would be affected. News coverage focused on the politics. Pharmaceutical company press releases were written for investors. Government documents were buried in Federal Register legalese.

RxTariff was built to fill that gap. We believe every patient deserves a clear, simple answer to a simple question: will my prescription cost more? This tool gives you that answer in seconds, using real government data from OpenFDA and the CMS NADAC database.

What This Tool Does

RxTariff lets you search any prescription drug by name and instantly learn: its tariff tier under the Section 232 proclamation (100%, 15%, 10%, 0%, or fully exempt), the current government acquisition cost from the CMS NADAC database, whether your manufacturer has signed an MFN deal, and whether a generic or biosimilar alternative exists that is fully exempt from all tariffs.

We also maintain a searchable database of the top brand-name drugs in America with pre-calculated tariff statuses, so you don't have to read the fine print of a presidential proclamation to understand your situation.

Data Sources

Our data comes from authoritative government sources:

• OpenFDA Drug Label API — Drug names, manufacturers, generic equivalents, and product types. Updated continuously by the FDA. open.fda.gov
• CMS NADAC Database — National Average Drug Acquisition Cost. Weekly survey of what pharmacies actually pay for drugs. Published by the Centers for Medicare & Medicaid Services. data.medicaid.gov
• White House Proclamation (April 2, 2026) — The primary legal document establishing the tariff tiers, exemptions, and company agreements. Annexes I, II, and III detail the specific classifications.
• FDA Orange Book & Purple Book — The authoritative lists of patented brand-name drugs (Orange Book) and licensed biologics (Purple Book). These define which drugs qualify as "patented pharmaceutical articles" under the tariff.

Limitations & Disclaimer

This tool provides general information only. Tariff rates are based on the Section 232 Proclamation issued April 2, 2026 and may change as new company agreements are reached, legal challenges proceed, or the administration issues modifications. Country-of-manufacture data is not always publicly available from OpenFDA and may affect the accuracy of tariff tier assignments for some drugs.

NADAC prices represent pharmacy acquisition costs — what pharmacies pay manufacturers — not the final price patients pay. Your actual out-of-pocket cost depends on your insurance plan, copay structure, and whether the tariff is passed through to you versus absorbed by the supply chain.

RxTariff is not affiliated with the FDA, CMS, the White House, or any pharmaceutical company. This site is for informational purposes only. Always consult your doctor or pharmacist before making any changes to your medications.